Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes.

DuBrock HM, Salgia RJ, Sussman NL, Bartolome SD, Kadry Z, Mulligan DC, Jenkins S, Lackore K, Channick RN, Kawut SM, Krowka MJ.

Transplant Direct. 2019 May 22;5(6):e456. doi: 10.1097/TXD.0000000000000900. eCollection 2019 Jun.

2.

Use of Endobronchial Ultrasound for Bedside Diagnosis of Acute Pulmonary Embolism in a Critically Ill Patient.

Channick CL, Channick RN.

Chest. 2019 Mar;155(3):651-652. doi: 10.1016/j.chest.2018.11.013. No abstract available.

PMID:
30846074
3.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

4.

Quantification of the Pulmonary Vascular Response to Inhaled Nitric Oxide Using Noncontrast Computed Tomography Imaging.

Rahaghi FN, Winkler T, Kohli P, Nardelli P, Martí-Fuster B, Ross JC, Radhakrishnan R, Blackwater T, Ash SY, de La Bruere I, Diaz AA, Channick RN, Harris RS, Washko GR, San José Estépar R.

Circ Cardiovasc Imaging. 2019 Dec;12(1):e008338. doi: 10.1161/CIRCIMAGING.118.008338. No abstract available.

PMID:
30632391
5.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

6.

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.

Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB.

Chest. 2018 Oct;154(4):848-861. doi: 10.1016/j.chest.2018.04.027. Epub 2018 Apr 26.

7.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

8.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

9.

Quantifying the learning curve for pulmonary thromboendarterectomy.

Sihag S, Le B, Witkin AS, Rodriguez-Lopez JM, Villavicencio MA, Vlahakes GJ, Channick RN, Wright CD.

J Cardiothorac Surg. 2017 Dec 28;12(1):121. doi: 10.1186/s13019-017-0686-1.

10.

Does the Time of Day a Pulmonary Embolism Response Team Is Activated Affect Time to Intervention or Outcome?

McNeill JN, Witkin AS, Chang Y, Kabrhel C, Channick RN.

Chest. 2017 Dec;152(6):1353-1354. doi: 10.1016/j.chest.2017.09.033. No abstract available.

PMID:
29223267
11.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
12.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025.

13.

Predictors of Waitlist Mortality in Portopulmonary Hypertension.

DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN.

Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.

14.

Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.

DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, Curry MP, VanderLaan PA, Zsengeller ZK, Pernicone E, Preston IR, Yu PB, Nikolic I, Xu D, Thadhani RI, Channick RN, Ananth Karumanchi S.

Pulm Circ. 2016 Dec;6(4):498-507. doi: 10.1086/688489.

15.

Electric Plasma-generated Nitric Oxide: Hemodynamic Effects in Patients with Pulmonary Hypertension.

Berra L, Rodriguez-Lopez J, Rezoagli E, Yu B, Fisher DF, Semigran MJ, Bloch DB, Channick RN, Zapol WM.

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1168-1170. No abstract available.

16.

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.

Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O.

Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Erratum in: Chest. 2018 May;153(5):1287.

17.

New paradigm for pulmonary arterial hypertension treatment.

Tamura Y, Channick RN.

Curr Opin Pulm Med. 2016 Sep;22(5):429-33. doi: 10.1097/MCP.0000000000000308. Review.

PMID:
27434819
18.

Pulmonary hypertension.

Humbert M, Channick RN.

Curr Opin Pulm Med. 2016 Sep;22(5):399. doi: 10.1097/MCP.0000000000000309. No abstract available.

PMID:
27428648
19.

Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM Study.

Tapson VF, Platt DM, Xia F, Teal SA, de la Orden M, Divers CH, Satler CA, Joish VN, Channick RN.

Am J Med. 2016 Sep;129(9):978-985.e2. doi: 10.1016/j.amjmed.2016.03.006. Epub 2016 Apr 1.

PMID:
27046247
20.

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.

Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ.

Eur Respir J. 2015 Dec;46(6):1711-20. doi: 10.1183/13993003.00364-2015. Epub 2015 Oct 22.

21.

Pulmonary capillary hemangiomatosis: the role of invasive cardiopulmonary exercise testing.

DuBrock HM, Kradin RL, Rodriguez-Lopez JM, Channick RN.

Pulm Circ. 2015 Sep;5(3):580-6. doi: 10.1086/682227.

22.

Pulmonary Hypertension and Right Ventricular Failure in Emergency Medicine.

Wilcox SR, Kabrhel C, Channick RN.

Ann Emerg Med. 2015 Dec;66(6):619-28. doi: 10.1016/j.annemergmed.2015.07.525. Epub 2015 Sep 3. Review.

PMID:
26342901
23.

Development of macitentan for the treatment of pulmonary arterial hypertension.

Selej M, Romero AJ, Channick RN, Clozel M.

Ann N Y Acad Sci. 2015 Nov;1358:68-81. doi: 10.1111/nyas.12856. Epub 2015 Aug 20. Review.

PMID:
26291180
24.

The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints.

LeVarge BL, Channick RN.

Curr Opin Pulm Med. 2015 Sep;21(5):438-45. doi: 10.1097/MCP.0000000000000197. Review.

PMID:
26176969
25.

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM.

Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.

26.

Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism.

Witkin AS, Channick RN.

Curr Cardiol Rep. 2015 Aug;17(8):63. doi: 10.1007/s11886-015-0621-9. Review.

PMID:
26099554
27.

Leaflet area as a determinant of tricuspid regurgitation severity in patients with pulmonary hypertension.

Afilalo J, Grapsa J, Nihoyannopoulos P, Beaudoin J, Gibbs JS, Channick RN, Langleben D, Rudski LG, Hua L, Handschumacher MD, Picard MH, Levine RA.

Circ Cardiovasc Imaging. 2015 May;8(5). pii: e002714. doi: 10.1161/CIRCIMAGING.114.002714.

28.

What's new in the treatment of portopulmonary hypertension?

DuBrock HM, Channick RN, Krowka MJ.

Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):983-92. doi: 10.1586/17474124.2015.1035647. Epub 2015 Apr 16. Review.

PMID:
25882070
29.

Effect of macitentan on hospitalizations: results from the SERAPHIN trial.

Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N.

JACC Heart Fail. 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11.

30.

Chronic thromboembolic pulmonary hypertension: evolution in management.

LeVarge BL, Channick RN.

Curr Opin Pulm Med. 2014 Sep;20(5):400-8. doi: 10.1097/MCP.0000000000000088. Review.

PMID:
25093673
31.

Macitentan for the treatment of pulmonary arterial hypertension.

DuBrock HM, Channick RN.

Expert Rev Respir Med. 2014 Aug;8(4):393-9. doi: 10.1586/17476348.2014.937708. Epub 2014 Jul 6. Review.

PMID:
24998329
32.

Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension.

LeVarge BL, Pomerantsev E, Channick RN.

Eur Respir J. 2014 Aug;44(2):425-34. doi: 10.1183/09031936.00209313. Epub 2014 Jun 12.

33.

Case records of the Massachusetts General Hospital. Case 9-2014. A 34-year-old woman with increasing dyspnea.

Saukkonen K, Tan TC, Sharma A, Channick RN, Murali MR, Zukerberg LR.

N Engl J Med. 2014 Mar 20;370(12):1149-57. doi: 10.1056/NEJMcpc1305992. No abstract available. Erratum in: N Engl J Med. 2014 Jun 5;370(23):2253.

PMID:
24645948
34.

A multidisciplinary pulmonary embolism response team.

Kabrhel C, Jaff MR, Channick RN, Baker JN, Rosenfield K.

Chest. 2013 Nov;144(5):1738-1739. doi: 10.1378/chest.13-1562. No abstract available.

PMID:
24189880
35.

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.

Channick RN, Frantz RP, Kawut SM, Palevsky H, Tumuluri R, Sulica R, Lauto PO, Benton WW, de Boisblanc B.

Pulm Circ. 2013 Apr;3(2):381-8. doi: 10.4103/2045-8932.114768.

36.

Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.

Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB.

Pulm Circ. 2013 Apr;3(2):369-80. doi: 10.4103/2045-8932.110445.

37.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators.

N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

38.

Pulmonary hypertension in patients with chronic and end-stage kidney disease.

Sise ME, Courtwright AM, Channick RN.

Kidney Int. 2013 Oct;84(4):682-92. doi: 10.1038/ki.2013.186. Epub 2013 Jun 5. Review.

39.

Combination therapy in pulmonary arterial hypertension.

Channick RN.

Am J Cardiol. 2013 Apr 16;111(8 Suppl):16C-20C. doi: 10.1016/j.amjcard.2013.01.320.

PMID:
23558025
40.

Postradiofrequency ablation inflammatory pseudotumor associated with pulmonary venoocclusive disease: case report and review of the literature.

Kovach AE, Cheng GZ, Channick CL, Channick RN, Muniappan A, Gaissert HA, Kradin RL.

Ann Diagn Pathol. 2013 Oct;17(5):466-9. doi: 10.1016/j.anndiagpath.2012.11.002. Epub 2013 Jan 22. Review.

PMID:
23352326
41.

Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.

Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ.

Cardiovasc Ther. 2013 Feb;31(1):38-44. doi: 10.1111/1755-5922.12008.

42.

Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap.

McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ; Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI) Investigators.

Chest. 2013 Feb 1;143(2):324-332. doi: 10.1378/chest.11-3060.

PMID:
22910999
43.

Inhaled treprostinil for the treatment of pulmonary arterial hypertension.

LeVarge BL, Channick RN.

Expert Rev Respir Med. 2012 Jun;6(3):255-65. doi: 10.1586/ers.12.23. Review.

PMID:
22788940
44.

Case records of the Massachusetts General Hospital. Case 11-2012. A 60-year-old man with weakness, rash, and renal failure.

Channick RN, Lorenzo ME, Wu CC, Hoang MP.

N Engl J Med. 2012 Apr 12;366(15):1434-43. doi: 10.1056/NEJMcpc1111571. No abstract available.

PMID:
22494124
45.

Inhaled treprostinil: a therapeutic review.

Channick RN, Voswinckel R, Rubin LJ.

Drug Des Devel Ther. 2012;6:19-28. doi: 10.2147/DDDT.S19281. Epub 2012 Jan 24. Review.

46.

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.

Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.

J Heart Lung Transplant. 2011 Dec;30(12):1327-33. doi: 10.1016/j.healun.2011.08.019.

PMID:
22055098
47.

The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.

Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A; Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators.

Ann Rheum Dis. 2012 Feb;71(2):249-52. doi: 10.1136/annrheumdis-2011-200265. Epub 2011 Oct 13.

PMID:
21998119
48.

Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomy.

Kerr KM, Auger WR, Marsh JJ, Devendra G, Spragg RG, Kim NH, Channick RN, Jamieson SW, Madani MM, Manecke GR, Roth DM, Shragg GP, Fedullo PF.

Chest. 2012 Jan;141(1):27-35. doi: 10.1378/chest.10-2639. Epub 2011 Aug 11.

49.

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.

J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027.

50.

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.

Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S85-96. doi: 10.1016/j.jacc.2009.04.008. Review.

Supplemental Content

Loading ...
Support Center